HEADER HYDROLASE 26-JUN-17 5WA8 TITLE HUMAN HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) H112N TITLE 2 MUTANT NUCLEOSIDE L-ALA PHOSPHORAMIDATE SUBSTRATE COMPLEX COMPND MOL_ID: 1; COMPND 2 MOLECULE: HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN 1; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: ADENOSINE 5'-MONOPHOSPHORAMIDASE,PROTEIN KINASE C INHIBITOR COMPND 5 1,PROTEIN KINASE C-INTERACTING PROTEIN 1,PKCI-1; COMPND 6 EC: 3.-.-.-; COMPND 7 ENGINEERED: YES; COMPND 8 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: HINT1, HINT, PKCI1, PRKCNH1; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: ROSETTA 2 PLYSS; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PMCSG7 KEYWDS HISTIDINE TRIAD, HYDROLASE EXPDTA X-RAY DIFFRACTION AUTHOR K.M.MAIZE,B.C.FINZEL REVDAT 3 04-OCT-23 5WA8 1 JRNL REVDAT 2 22-NOV-17 5WA8 1 JRNL REVDAT 1 18-OCT-17 5WA8 0 JRNL AUTH K.M.MAIZE,R.SHAH,A.STROM,S.KUMARAPPERUMA,A.ZHOU,C.R.WAGNER, JRNL AUTH 2 B.C.FINZEL JRNL TITL A CRYSTAL STRUCTURE BASED GUIDE TO THE DESIGN OF HUMAN JRNL TITL 2 HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1 (HHINT1) JRNL TITL 3 ACTIVATED PROTIDES. JRNL REF MOL. PHARM. V. 14 3987 2017 JRNL REFN ESSN 1543-8392 JRNL PMID 28968488 JRNL DOI 10.1021/ACS.MOLPHARMACEUT.7B00664 REMARK 2 REMARK 2 RESOLUTION. 1.30 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.30 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 34.35 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.360 REMARK 3 COMPLETENESS FOR RANGE (%) : 95.6 REMARK 3 NUMBER OF REFLECTIONS : 53643 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.155 REMARK 3 R VALUE (WORKING SET) : 0.154 REMARK 3 FREE R VALUE : 0.170 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.110 REMARK 3 FREE R VALUE TEST SET COUNT : 2740 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 34.3608 - 3.5276 0.96 2652 146 0.1407 0.1577 REMARK 3 2 3.5276 - 2.8003 0.96 2566 161 0.1601 0.1682 REMARK 3 3 2.8003 - 2.4465 0.97 2590 149 0.1643 0.1772 REMARK 3 4 2.4465 - 2.2228 0.97 2606 119 0.1437 0.1524 REMARK 3 5 2.2228 - 2.0635 0.96 2526 163 0.1506 0.1629 REMARK 3 6 2.0635 - 1.9419 0.97 2595 134 0.1474 0.1394 REMARK 3 7 1.9419 - 1.8446 0.97 2598 105 0.1470 0.1644 REMARK 3 8 1.8446 - 1.7643 0.96 2548 141 0.1533 0.1767 REMARK 3 9 1.7643 - 1.6964 0.96 2557 146 0.1536 0.1820 REMARK 3 10 1.6964 - 1.6379 0.96 2556 144 0.1533 0.1847 REMARK 3 11 1.6379 - 1.5867 0.96 2520 152 0.1506 0.1723 REMARK 3 12 1.5867 - 1.5413 0.96 2573 129 0.1515 0.1638 REMARK 3 13 1.5413 - 1.5007 0.95 2507 145 0.1548 0.1922 REMARK 3 14 1.5007 - 1.4641 0.95 2499 134 0.1597 0.1883 REMARK 3 15 1.4641 - 1.4308 0.95 2536 122 0.1604 0.1869 REMARK 3 16 1.4308 - 1.4004 0.95 2546 122 0.1738 0.1850 REMARK 3 17 1.4004 - 1.3724 0.94 2479 131 0.1760 0.1894 REMARK 3 18 1.3724 - 1.3465 0.94 2519 125 0.1724 0.1871 REMARK 3 19 1.3465 - 1.3224 0.93 2485 135 0.1834 0.1905 REMARK 3 20 1.3224 - 1.3000 0.94 2445 137 0.2038 0.2287 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.110 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 16.680 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 9.32 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 13.14 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.006 1866 REMARK 3 ANGLE : 0.942 2545 REMARK 3 CHIRALITY : 0.085 279 REMARK 3 PLANARITY : 0.005 333 REMARK 3 DIHEDRAL : 13.294 701 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 5WA8 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 28-JUN-17. REMARK 100 THE DEPOSITION ID IS D_1000227214. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 19-FEB-17 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.4-6.7 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.000 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 53652 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.300 REMARK 200 RESOLUTION RANGE LOW (A) : 39.633 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.6 REMARK 200 DATA REDUNDANCY : 3.300 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 16.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.30 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.30 REMARK 200 COMPLETENESS FOR SHELL (%) : 87.9 REMARK 200 DATA REDUNDANCY IN SHELL : 3.40 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 3TW2 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 39.99 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.05 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 100 MM MES, 38% PEG 8000, VAPOR REMARK 280 DIFFUSION, HANGING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 39.20550 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 22.99400 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 39.20550 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 22.99400 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3970 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9380 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -29.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH B 397 LIES ON A SPECIAL POSITION. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 SER A -2 REMARK 465 ASN A -1 REMARK 465 ALA A 0 REMARK 465 MET A 1 REMARK 465 ALA A 2 REMARK 465 ASP A 3 REMARK 465 GLU A 4 REMARK 465 ILE A 5 REMARK 465 ALA A 6 REMARK 465 LYS A 7 REMARK 465 ALA A 8 REMARK 465 GLN A 9 REMARK 465 VAL A 10 REMARK 465 ALA A 11 REMARK 465 SER B -2 REMARK 465 ASN B -1 REMARK 465 ALA B 0 REMARK 465 MET B 1 REMARK 465 ALA B 2 REMARK 465 ASP B 3 REMARK 465 GLU B 4 REMARK 465 ILE B 5 REMARK 465 ALA B 6 REMARK 465 LYS B 7 REMARK 465 ALA B 8 REMARK 465 GLN B 9 REMARK 465 VAL B 10 REMARK 465 ALA B 11 REMARK 465 ARG B 12 REMARK 465 PRO B 13 REMARK 465 GLY B 14 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG A 12 CG CD NE CZ NH1 NH2 REMARK 470 ASP A 16 CG OD1 OD2 REMARK 470 LYS A 92 CG CD CE NZ REMARK 470 LYS B 92 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH B 357 O HOH B 394 2.16 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 9ZA A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue CL B 201 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 5IPB RELATED DB: PDB REMARK 900 5IPB CONTAINS THE SAME MUTANT PROTEIN IN APO FORM. REMARK 900 RELATED ID: 5IPC RELATED DB: PDB REMARK 900 5IPC CONTAINS THE SAME MUTANT PROTEIN COMPLEXED WITH A REMARK 900 PHOSPHORAMIDATE LIGAND. REMARK 900 RELATED ID: 5KMA RELATED DB: PDB REMARK 900 5KMA CONTAINS THE SAME MUTANT PROTEIN COMPLEXED WITH AN D-TRP REMARK 900 PHOSPHORAMIDATE. REMARK 900 RELATED ID: 5KMB RELATED DB: PDB REMARK 900 5KMB CONTAINS THE SAME MUTANT PROTEIN COMPLEXED WITH AN L-TRP REMARK 900 PHOSPHORAMIDATE. REMARK 900 RELATED ID: 3TW2 RELATED DB: PDB REMARK 900 3TW2 CONTAINS THE WILD-TYPE PROTEIN COMPLEXED WITH AMP. DBREF 5WA8 A 1 126 UNP P49773 HINT1_HUMAN 1 126 DBREF 5WA8 B 1 126 UNP P49773 HINT1_HUMAN 1 126 SEQADV 5WA8 SER A -2 UNP P49773 EXPRESSION TAG SEQADV 5WA8 ASN A -1 UNP P49773 EXPRESSION TAG SEQADV 5WA8 ALA A 0 UNP P49773 EXPRESSION TAG SEQADV 5WA8 ASN A 112 UNP P49773 HIS 112 ENGINEERED MUTATION SEQADV 5WA8 SER B -2 UNP P49773 EXPRESSION TAG SEQADV 5WA8 ASN B -1 UNP P49773 EXPRESSION TAG SEQADV 5WA8 ALA B 0 UNP P49773 EXPRESSION TAG SEQADV 5WA8 ASN B 112 UNP P49773 HIS 112 ENGINEERED MUTATION SEQRES 1 A 129 SER ASN ALA MET ALA ASP GLU ILE ALA LYS ALA GLN VAL SEQRES 2 A 129 ALA ARG PRO GLY GLY ASP THR ILE PHE GLY LYS ILE ILE SEQRES 3 A 129 ARG LYS GLU ILE PRO ALA LYS ILE ILE PHE GLU ASP ASP SEQRES 4 A 129 ARG CYS LEU ALA PHE HIS ASP ILE SER PRO GLN ALA PRO SEQRES 5 A 129 THR HIS PHE LEU VAL ILE PRO LYS LYS HIS ILE SER GLN SEQRES 6 A 129 ILE SER VAL ALA GLU ASP ASP ASP GLU SER LEU LEU GLY SEQRES 7 A 129 HIS LEU MET ILE VAL GLY LYS LYS CYS ALA ALA ASP LEU SEQRES 8 A 129 GLY LEU ASN LYS GLY TYR ARG MET VAL VAL ASN GLU GLY SEQRES 9 A 129 SER ASP GLY GLY GLN SER VAL TYR HIS VAL ASN LEU HIS SEQRES 10 A 129 VAL LEU GLY GLY ARG GLN MET HIS TRP PRO PRO GLY SEQRES 1 B 129 SER ASN ALA MET ALA ASP GLU ILE ALA LYS ALA GLN VAL SEQRES 2 B 129 ALA ARG PRO GLY GLY ASP THR ILE PHE GLY LYS ILE ILE SEQRES 3 B 129 ARG LYS GLU ILE PRO ALA LYS ILE ILE PHE GLU ASP ASP SEQRES 4 B 129 ARG CYS LEU ALA PHE HIS ASP ILE SER PRO GLN ALA PRO SEQRES 5 B 129 THR HIS PHE LEU VAL ILE PRO LYS LYS HIS ILE SER GLN SEQRES 6 B 129 ILE SER VAL ALA GLU ASP ASP ASP GLU SER LEU LEU GLY SEQRES 7 B 129 HIS LEU MET ILE VAL GLY LYS LYS CYS ALA ALA ASP LEU SEQRES 8 B 129 GLY LEU ASN LYS GLY TYR ARG MET VAL VAL ASN GLU GLY SEQRES 9 B 129 SER ASP GLY GLY GLN SER VAL TYR HIS VAL ASN LEU HIS SEQRES 10 B 129 VAL LEU GLY GLY ARG GLN MET HIS TRP PRO PRO GLY HET 9ZA A 201 29 HET CL B 201 1 HETNAM 9ZA [(2~{R},3~{S},4~{R},5~{R})-5-(6-AMINOPURIN-9-YL)-3,4- HETNAM 2 9ZA BIS(OXIDANYL)OXOLAN-2-YL]METHOXY-~{N}-[(2~{S})-1- HETNAM 3 9ZA METHOXY-1-OXIDANYLIDENE-PROPAN-2-YL]PHOSPHONAMIDIC HETNAM 4 9ZA ACID HETNAM CL CHLORIDE ION FORMUL 3 9ZA C14 H21 N6 O8 P FORMUL 4 CL CL 1- FORMUL 5 HOH *237(H2 O) HELIX 1 AA1 THR A 17 ARG A 24 1 8 HELIX 2 AA2 GLN A 62 ALA A 66 5 5 HELIX 3 AA3 GLU A 67 ASP A 69 5 3 HELIX 4 AA4 ASP A 70 LEU A 88 1 19 HELIX 5 AA5 GLY A 101 GLY A 105 1 5 HELIX 6 AA6 THR B 17 ARG B 24 1 8 HELIX 7 AA7 GLN B 62 ALA B 66 5 5 HELIX 8 AA8 GLU B 67 ASP B 69 5 3 HELIX 9 AA9 ASP B 70 LEU B 88 1 19 HELIX 10 AB1 GLY B 101 GLY B 105 1 5 SHEET 1 AA110 ILE A 31 GLU A 34 0 SHEET 2 AA110 CYS A 38 HIS A 42 -1 O ALA A 40 N ILE A 32 SHEET 3 AA110 THR A 50 PRO A 56 -1 O LEU A 53 N PHE A 41 SHEET 4 AA110 LEU A 113 GLY A 117 -1 O VAL A 115 N PHE A 52 SHEET 5 AA110 TYR A 94 GLU A 100 -1 N VAL A 97 O HIS A 114 SHEET 6 AA110 TYR B 94 GLU B 100 -1 O VAL B 98 N MET A 96 SHEET 7 AA110 LEU B 113 GLY B 117 -1 O HIS B 114 N VAL B 97 SHEET 8 AA110 THR B 50 PRO B 56 -1 N VAL B 54 O LEU B 113 SHEET 9 AA110 CYS B 38 HIS B 42 -1 N PHE B 41 O LEU B 53 SHEET 10 AA110 ILE B 31 GLU B 34 -1 N PHE B 33 O ALA B 40 CISPEP 1 TRP A 123 PRO A 124 0 -0.30 CISPEP 2 TRP B 123 PRO B 124 0 6.11 SITE 1 AC1 23 ILE A 18 PHE A 19 PHE A 41 HIS A 42 SITE 2 AC1 23 ASP A 43 ILE A 44 SER A 45 LEU A 53 SITE 3 AC1 23 ASN A 99 GLY A 105 GLN A 106 SER A 107 SITE 4 AC1 23 VAL A 108 ASN A 112 HIS A 114 HOH A 337 SITE 5 AC1 23 HOH A 339 HOH A 344 HOH A 348 HOH A 351 SITE 6 AC1 23 HOH A 354 HOH A 389 TRP B 123 SITE 1 AC2 5 ASN B 99 GLN B 106 SER B 107 ASN B 112 SITE 2 AC2 5 HIS B 114 CRYST1 78.411 45.988 64.209 90.00 94.77 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.012753 0.000000 0.001065 0.00000 SCALE2 0.000000 0.021745 0.000000 0.00000 SCALE3 0.000000 0.000000 0.015628 0.00000